Epygen looking to raise Rs 300 Cr to propel Biosimilars in India

By / 2 years ago / News Update / 6 Comments
Epygen looking to raise Rs 300 Cr to propel Biosimilars in India

After having spent seven years on technology incubation in India and more than a decade of Biotechnology research abroad, Epygen Biotech, one of the leading privately held biotechnology companies in India plans to raise Rs 300 crore in the next three years to fuel  launch of its exciting Biosimilar pipeline.

The funding will provide Epygen with the best possible conditions to propel clinical trial programs of its pipeline molecules in the field of Oncology and Cardiology, which are showing substantial promise in protein expression and purification. With several decades of recombinant protein background, the company aims to take a lead role in the biosimilar field in the region. From a pipeline full with E Coli and mammalian proteins, the company has chosen to launch a stepping stone Biosimilar Recombinant Streptokinase (rSK) for the cardiovascular segment  in India by 2019. This product is of utmost national interest as 17 lakh people die of heart attack in India every year and other thrombolytic proteins is more than ten times in cost. This technology is befitting to the current  programme assuring “Healtahcare for all”.

The company is upgrading its R&D capabilities setting up a 1,00,000 sqft Biopharmaceutical facility in Patalganga, Maharashtra, where Phase-I of the Project is dedicated to E Coli based biosimilars for Cardiovascular, Oncology and Rheumatology and Phase-II to make mammalian cell based monoclonal antibodies for Oncology, jointly targeting more than $ 10 billion market. The fresh fund infusion would be utlilized for clinical trials of the pipeline molecules and securing intellectual property (IP) for a range of medium and late stage technologies for Novel Biological Entities in Oncology and CNS segments.

Biosimilar pipeline progress map:

Mr. Debayan Ghosh, President and Founder, Epygen said, “The Indian market has doubled in size in the biosimilar space over the past years, and aiming at catching up with regional players like Korea and even exceed them by 2025. There is a $30 billion pie on the plate, however, the entry barrier will only get stiffer as regulatory challenges emerge in the lights of the developed world”. Mr Ghosh is an ex Biocon, who subsequently steered a US Biotechnology company through NYSE, prior to founding Epygen in 2006.

admin

admin

The author didn't add any Information to his profile yet.

6 Comments

  • quest bars cheap coupon twitter03. Dec, 2019

    You can certainly see your enthusiasm in the article you write.
    The world hopes for even more passionate writers like you who aren’t afraid to mention how they believe.
    All the time go after your heart.

  • quest bars cheap coupon twitter02. Dec, 2019

    Spot on with this write-up, I actually believe this amazing site
    needs much more attention. I’ll probably be back again to read
    more, thanks for the information!

  • quest bars cheap01. Dec, 2019

    Ahaa, its pleasant dialogue about this paragraph at this place at
    this weblog, I have read all that, so at this time me also
    commenting at this place.

  • ps4 games29. Nov, 2019

    I have to thank you for the efforts you have put in writing this site.
    I really hope to view the same high-grade content by you
    later on as well. In fact, your creative writing abilities has motivated me to get my own, personal website now 😉

  • of coconut oil25. Nov, 2019

    My partner and I stumbled over here different web page and thought I might as well check things out.
    I like what I see so now i’m following you.
    Look forward to looking over your web page yet again.

  • http://tinyurl.com/yx6wwfxw24. Nov, 2019

    Normally I do not learn article on blogs, however I would like to say that this write-up very forced
    me to try and do it! Your writing taste has been surprised me.
    Thank you, quite great post.

Leave a comment

Your email address will not be published. Required fields are marked. *